title: [Pathological complete response in advanced gastric carcinoma by S-1/CDDP combination chemotherapy].
abstract: A59 -year-old woman was referred to our hospital for a close examination and treatment of an advanced gastric carcinoma. A physical examination and CT scan showed that the right cervical and axillar lymph nodes were swelling, and a histopathological examination of the axillar lymph node revealed metastatic growth of the gastric carcinoma (Stage IV). Then, we started S-1/CDDP combination chemotherapy. S-1 (80 mg/m2/day)was orally administered for 3 weeks followed by 2 weeks of rest, and CDDP (60 mg/m2) was administered by drip on day 8. Since the distant metastases were greatly reduced after 6 courses of combination therapy, a distal gastrectomy with lymph nodes dissection (D2) was performed. Histopathological examination of the resected tissues revealed no residual cancer cells, suggesting a pathologically complete response. The clinical course after the operation went well without any complications, and the patient is alive with no evidence of recurrence 1 year after surgery. S-1/CDDP combination chemotherapy appears to be one of the effective treatments for advanced gastric carcinoma.
authors.affiliation: Division of Surgery, Saiseikai Central Hospital, Japan.
authors.forename: Fumiki
authors.initials: F
authors.lastname: Toriumi
authors.forename: Shigenori
authors.initials: S
authors.lastname: Ei
authors.forename: Hidena
authors.initials: H
authors.lastname: Takahashi
authors.forename: Rei
authors.initials: R
authors.lastname: Okada
authors.forename: Kyohei
authors.initials: K
authors.lastname: Masai
authors.forename: Mikiko
authors.initials: M
authors.lastname: Mito
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishimaru
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Mizuno
authors.forename: Kan
authors.initials: K
authors.lastname: Handa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamanashi
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Koshida
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Akamatsu
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Motegi
authors.forename: Toshihide
authors.initials: T
authors.lastname: Tajima
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Mukai
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Shimoyama
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin